Back to results
US 10,226,509 B2Granted
Lymphangiogenesis inhibitors for cancer and for graft survival
AssigneeTufts University
InventorsNoorjahan Panjwani, Wei-Sheng Chen
Life of this patent
Estimating the term…
Abstract
Compositions and methods are provided for treating and/or preventing lymphangiogenesis in a subject by using an inhibitor of a galectin-8 protein in an amount effective to inhibit or to modulate an activity of the galectin-8 protein or a portion thereof sufficient to inhibit the lymphangiogenesis associated with cancer, corneal injury, dry eye disease, inflammation, lymphedema, organ rejection or graft rejection.
Claims7
A method for treating or preventing lymphangiogenesis in a subject, the method comprising:
- selecting an inhibitor of a galectin-8 protein or a portion thereof, wherein the inhibitor is a dominant negative inhibitor or a saccharide inhibitor selected from Thymine DNA glycosylase (TDG), 3′-sialyl lactose, and Maackia amurensis II (MAA II);
- administering a therapeutically effective amount of a pharmaceutical composition to the subject, wherein the composition comprises the inhibitor;
- and,
- measuring a decrease in a lymphangiogenesis marker in the subject.
1 more element
Dependencies are inferred from the claim text.